FindTrial
Sign In

CS-866DM phase 3 comparative study (ORIENT)

CS-866DM phase 3 comparative study (ORIENT)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220027
Enrollment
Unknown
Registered
2005-09-05
Start date
2005-09-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes and nephropathy

Interventions

investigational material(s) Generic name etc : CS-866DM INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material : Or

Sponsors

DAIICHISANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: -Patient, age 30-70. -Albumin-to-creatinine ratio >=300 mg/g-creatinine in first morning urinalysis -Serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men

Exclusion criteria

Exclusion criteria: Exclusion criteria: -History of cerebrovascular or cardiovascular disease -Rapid progression of kidney disease within 3 months -Patient with extremely poor glycemic control

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026